PharmaLex Group expands regulatory footprint

The appointment of Laura Monkiene, will enhances the Regulatory Outsourcing Team, according to PharmaLex.

PharmaLex Group, one of the largest providers for Development Consulting, Regulatory Affairs, Quality Management & Compliance and Pharmacovigilance worldwide, has enhanced its Regulatory Outsourcing Team with the addition of Laura Monkiene.

Laura Monkiene joins PharmaLex as Director/Principal Consultant. With her extensive experience, she will lead local and global projects and support clients worldwide with regulatory affairs, medical writing and pharmacovigilance service demands.

Monkiene brings a great knowledge base and has a clear understanding of the global, specifically Russia and CIS regulatory landscape.

Her responsibilities will include management of new and strategically important projects, communication with regulatory agencies and management of local PharmaLex representatives in the CIS region.

“The CIS region is a growing and important market and we are building on Laura’s management capabilities to increase our local presence and team. We are excited to welcome Laura to the PharmaLex Group,” explained Dr Kirsten Jacobs, Executive VP Regulatory Affairs.

Monkiene added: “The CIS region is undergoing major changes in the regulatory framework related to the Eurasian Economic Union (EAEU) regulations. Exceptional focus should be given to new process´ implementation and re-registrations of current portfolios before 31 December 2025. By strengthening our presence in the region we aim to support our customers to navigate through the changes as early and as comfortable as possible.”

Monkiene has a Masters Degree in Pharmacy from the Lithuanian University of Health Sciences and a second Masters Degree in Business Economics from Kaunas University of Technology.

The PharmaLex Group now has more than 700 employees, with 26 offices in 14 countries and more than 600 clients worldwide.

You may also like

Regulatory

The right validation model: practical considerations and applications

It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
Regulatory

European Commission adopts proposal to delay MDR deadlines

With thousands of outstanding conformity assessments for medical device certification under the Medical Device Regulation and limited capacity to manage these within the transition period, concerns about widespread product shortages in the EU market have been growing
Regulatory

Investment, outsourcing and globalisation: key trends for 2023

The start of 2023 has been challenging for the pharmaceutical industry. Economic constraints in Europe and the United States, staffing shortages, an increasingly complex regulatory environment and heightened competition for funding is putting pressure on companies
Regulatory

PharmaLex extends reach in Asia with Ascent merger

Headquartered in Tokyo, Ascent employs staff across Asia, and provides country-specific knowledge mixed with strategic advice from a global perspective
Regulatory

PharmaLex taps DocShifter for PDF generation

DocShifter is a document conversion and validation solution for pharmaceutical, biotech and medical device companies
Regulatory

Why Bayesian statistics is revolutionising pharmaceutical decision making

PharmaLex's Bruno Boulanger, Global Head of Statistics and Data Science, and Brad Carlin, Senior Adviser for Statistics and Data Science, explore the growing significance of Bayesian statistics in supporting decision-making across the development and regulatory processes and its potential to improve outcomes for the biopharmaceutical industry
Regulatory

EFSA declares titanium dioxide unsafe for food products

Thomas Eberwein, Head of Pharmaceutical Quality at Pharmalex, explains the EFSA’s recent decision to declare titanium dioxide unsafe for food products, and the implications for manufacturers
Subscribe now